{"entity":{"type":"insider","cik":"0001592380","url":"/insider/0001592380","json_url":"/insider/0001592380.json","name":"Thorp Clay","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":87,"n_filings":37,"first":"2016-06-07","last":"2025-02-24","span_basis":"filed_date"},"name_variants":[{"name":"Thorp Clay","source":"filing","n_filings":37,"first_seen":"2016-06-07","last_seen":"2025-02-24"}],"transactions":[{"id":4805397,"accession":"0001415889-25-005325","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-005325","line_url":"/filing/0001415889-25-005325#line-1","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15000.0,"shares_display":"15,000","price_per_share":0.92,"price_display":"0.92","price_state":"stated","total_value":13800.0,"total_display":"13,800.00","total_whole":"13,800","shares_owned_after":176141.0,"shares_owned_after_display":"176,141","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-24","filed_date":"2025-02-24","scope":"insider"},{"id":7954893,"accession":"0001209191-23-050480","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-050480","line_url":"/filing/0001209191-23-050480#line-1","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":0.86,"price_display":"0.86","price_state":"stated","total_value":8600.0,"total_display":"8,600.00","total_whole":"8,600","shares_owned_after":40522.0,"shares_owned_after_display":"40,522","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-25","filed_date":"2023-09-25","scope":"insider"},{"id":6279351,"accession":"0001209191-22-062338","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-062338","line_url":"/filing/0001209191-22-062338#line-1","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":14000.0,"shares_display":"14,000","price_per_share":1.019,"price_display":"1.02","price_state":"stated","total_value":14266.0,"total_display":"14,266.00","total_whole":"14,266","shares_owned_after":30522.0,"shares_owned_after_display":"30,522","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-21","filed_date":"2022-12-21","scope":"insider"},{"id":6767466,"accession":"0000899243-22-018491","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-018491","line_url":"/filing/0000899243-22-018491#line-2","is_derivative":false,"issuer_cik":"0001592380","issuer_name":"Vigil Neuroscience, Inc.","issuer_ticker":"VIGL","issuer_name_source":null,"issuer_url":"/issuer/0001592380","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":14893.0,"shares_display":"14,893","price_per_share":2.9671,"price_display":"2.97","price_state":"stated","total_value":44189.0203,"total_display":"44,189.02","total_whole":"44,189","shares_owned_after":1556030.0,"shares_owned_after_display":"1,556,030","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-05-17","filed_date":"2022-05-17","scope":"insider"},{"id":6767464,"accession":"0000899243-22-018491","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-018491","line_url":"/filing/0000899243-22-018491#line-1","is_derivative":false,"issuer_cik":"0001592380","issuer_name":"Vigil Neuroscience, Inc.","issuer_ticker":"VIGL","issuer_name_source":null,"issuer_url":"/issuer/0001592380","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":21802.0,"shares_display":"21,802","price_per_share":2.7622,"price_display":"2.76","price_state":"stated","total_value":60221.4844,"total_display":"60,221.48","total_whole":"60,221","shares_owned_after":1541137.0,"shares_owned_after_display":"1,541,137","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-05-16","filed_date":"2022-05-17","scope":"insider"},{"id":6840706,"accession":"0000899243-22-012485","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-012485","line_url":"/filing/0000899243-22-012485#line-1","is_derivative":false,"issuer_cik":"0001592380","issuer_name":"Vigil Neuroscience, Inc.","issuer_ticker":"VIGL","issuer_name_source":null,"issuer_url":"/issuer/0001592380","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3000.0,"shares_display":"3,000","price_per_share":7.2014,"price_display":"7.20","price_state":"stated","total_value":21604.2,"total_display":"21,604.20","total_whole":"21,604","shares_owned_after":3000.0,"shares_owned_after_display":"3,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-28","filed_date":"2022-03-28","scope":"insider"},{"id":6138848,"accession":"0000899243-22-001658","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-001658","line_url":"/filing/0000899243-22-001658#line-2","is_derivative":false,"issuer_cik":"0001592380","issuer_name":"Vigil Neuroscience, Inc.","issuer_ticker":"VIGL","issuer_name_source":null,"issuer_url":"/issuer/0001592380","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":265000.0,"shares_display":"265,000","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":3710000.0,"total_display":"3,710,000.00","total_whole":"3,710,000","shares_owned_after":1519335.0,"shares_owned_after_display":"1,519,335","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-11","filed_date":"2022-01-11","scope":"insider"},{"id":4374130,"accession":"0001169245-21-000080","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001169245-21-000080","line_url":"/filing/0001169245-21-000080#line-1","is_derivative":false,"issuer_cik":"0001169245","issuer_name":"PhaseBio Pharmaceuticals Inc","issuer_ticker":"PHAS","issuer_name_source":null,"issuer_url":"/issuer/0001169245","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":3.0,"price_display":"3.00","price_state":"stated","total_value":30000.0,"total_display":"30,000.00","total_whole":"30,000","shares_owned_after":32943.0,"shares_owned_after_display":"32,943","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-18","filed_date":"2021-08-18","scope":"insider"},{"id":9271863,"accession":"0001209191-22-062044","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-062044","line_url":"/filing/0001209191-22-062044#line-1","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":32873.0,"shares_display":"32,873","price_per_share":4.43,"price_display":"4.43","price_state":"stated","total_value":145627.39,"total_display":"145,627.39","total_whole":"145,627","shares_owned_after":4951547.0,"shares_owned_after_display":"4,951,547","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-10","filed_date":"2022-12-19","scope":"insider"},{"id":5520032,"accession":"0001209191-21-010259","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-010259","line_url":"/filing/0001209191-21-010259#line-1","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":32873.0,"shares_display":"32,873","price_per_share":4.43,"price_display":"4.43","price_state":"stated","total_value":145627.39,"total_display":"145,627.39","total_whole":"145,627","shares_owned_after":3433521.0,"shares_owned_after_display":"3,433,521","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-10","filed_date":"2021-02-12","scope":"insider"},{"id":2622430,"accession":"0001169245-20-000107","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001169245-20-000107","line_url":"/filing/0001169245-20-000107#line-2","is_derivative":false,"issuer_cik":"0001169245","issuer_name":"PhaseBio Pharmaceuticals Inc","issuer_ticker":"PHAS","issuer_name_source":null,"issuer_url":"/issuer/0001169245","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":3.5,"price_display":"3.50","price_state":"stated","total_value":7000.0,"total_display":"7,000.00","total_whole":"7,000","shares_owned_after":22943.0,"shares_owned_after_display":"22,943","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-24","filed_date":"2020-11-24","scope":"insider"},{"id":2622425,"accession":"0001169245-20-000107","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001169245-20-000107","line_url":"/filing/0001169245-20-000107#line-1","is_derivative":false,"issuer_cik":"0001169245","issuer_name":"PhaseBio Pharmaceuticals Inc","issuer_ticker":"PHAS","issuer_name_source":null,"issuer_url":"/issuer/0001169245","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3000.0,"shares_display":"3,000","price_per_share":3.67,"price_display":"3.67","price_state":"stated","total_value":11010.0,"total_display":"11,010.00","total_whole":"11,010","shares_owned_after":20943.0,"shares_owned_after_display":"20,943","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-23","filed_date":"2020-11-24","scope":"insider"},{"id":7979353,"accession":"0001209191-19-041112","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-19-041112","line_url":"/filing/0001209191-19-041112","is_derivative":false,"issuer_cik":"0001169245","issuer_name":"PhaseBio Pharmaceuticals Inc","issuer_ticker":"PHAS","issuer_name_source":null,"issuer_url":"/issuer/0001169245","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2908.0,"shares_display":"2,908","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":40712.0,"total_display":"40,712.00","total_whole":"40,712","shares_owned_after":1818638.0,"shares_owned_after_display":"1,818,638","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-07-01","filed_date":"2019-07-03","scope":"insider","n_lines":4},{"id":8417916,"accession":"0001209191-19-038324","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-19-038324","line_url":"/filing/0001209191-19-038324","is_derivative":false,"issuer_cik":"0001169245","issuer_name":"PhaseBio Pharmaceuticals Inc","issuer_ticker":"PHAS","issuer_name_source":null,"issuer_url":"/issuer/0001169245","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":5600.0,"total_display":"5,600.00","total_whole":"5,600","shares_owned_after":1820656.0,"shares_owned_after_display":"1,820,656","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-18","filed_date":"2019-06-20","scope":"insider","n_lines":4},{"id":6267912,"accession":"0001209191-18-061355","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-061355","line_url":"/filing/0001209191-18-061355#line-1","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8000.0,"shares_display":"8,000","price_per_share":1.36,"price_display":"1.36","price_state":"stated","total_value":10880.0,"total_display":"10,880.00","total_whole":"10,880","shares_owned_after":8000.0,"shares_owned_after_display":"8,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-06","filed_date":"2018-12-06","scope":"insider"},{"id":6498877,"accession":"0001209191-18-061125","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-061125","line_url":"/filing/0001209191-18-061125#line-1","is_derivative":false,"issuer_cik":"0001169245","issuer_name":"PhaseBio Pharmaceuticals Inc","issuer_ticker":"PHAS","issuer_name_source":null,"issuer_url":"/issuer/0001169245","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4000.0,"shares_display":"4,000","price_per_share":3.13,"price_display":"3.13","price_state":"stated","total_value":12520.0,"total_display":"12,520.00","total_whole":"12,520","shares_owned_after":15799.0,"shares_owned_after_display":"15,799","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-04","filed_date":"2018-12-06","scope":"insider"},{"id":6142726,"accession":"0001209191-18-056051","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-18-056051","line_url":"/filing/0001209191-18-056051","is_derivative":false,"issuer_cik":"0001169245","issuer_name":"PhaseBio Pharmaceuticals Inc","issuer_ticker":"PHAS","issuer_name_source":null,"issuer_url":"/issuer/0001169245","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300000.0,"shares_display":"300,000","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":1500000.0,"total_display":"1,500,000.00","total_whole":"1,500,000","shares_owned_after":416481.0,"shares_owned_after_display":"416,481","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-10-22","filed_date":"2018-10-24","scope":"insider","n_lines":3},{"id":6016951,"accession":"0001209191-18-034839","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-034839","line_url":"/filing/0001209191-18-034839","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"G1 Therapeutics, Inc.","issuer_ticker":"GTHX","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"LEE KENNETH B JR; Thorp Clay; Hatteras Venture Partners IV SBIC, LP; Crumpler John; Hatteras Venture Advisors IV SBIC, LLC; Reed Douglas MD; INGRAM ROBERT ALEXANDER","owner_display_name":"LEE KENNETH B JR","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":800000.0,"shares_display":"800,000","price_per_share":48.0,"price_display":"48.00","price_state":"stated","total_value":38400000.0,"total_display":"38,400,000.00","total_whole":"38,400,000","shares_owned_after":3279421.0,"shares_owned_after_display":"3,279,421","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-30","filed_date":"2018-06-01","scope":"insider","n_lines":2},{"id":6454685,"accession":"0001209191-18-032789","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-18-032789","line_url":"/filing/0001209191-18-032789","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"G1 Therapeutics, Inc.","issuer_ticker":"GTHX","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"Reed Douglas MD; LEE KENNETH B JR; Thorp Clay; Crumpler John; INGRAM ROBERT ALEXANDER; Hatteras Venture Partners IV SBIC, LP; Hatteras Venture Advisors IV SBIC, LLC","owner_display_name":"Reed Douglas MD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":50.5,"price_display":"50.50","price_state":"stated","total_value":25250.0,"total_display":"25,250.00","total_whole":"25,250","shares_owned_after":4037737.0,"shares_owned_after_display":"4,037,737","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-23","filed_date":"2018-05-23","scope":"insider","n_lines":2},{"id":6454679,"accession":"0001209191-18-032789","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-18-032789","line_url":"/filing/0001209191-18-032789","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"G1 Therapeutics, Inc.","issuer_ticker":"GTHX","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"Reed Douglas MD; LEE KENNETH B JR; Thorp Clay; Crumpler John; INGRAM ROBERT ALEXANDER; Hatteras Venture Partners IV SBIC, LP; Hatteras Venture Advisors IV SBIC, LLC","owner_display_name":"Reed Douglas MD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5900.0,"shares_display":"5,900","price_per_share":50.85020616949153,"price_display":"50.85","price_state":"stated","total_value":300016.2164,"total_display":"300,016.22","total_whole":"300,016","shares_owned_after":4038519.0,"shares_owned_after_display":"4,038,519","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-22","filed_date":"2018-05-23","scope":"insider","n_lines":2},{"id":6454673,"accession":"0001209191-18-032789","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-18-032789","line_url":"/filing/0001209191-18-032789","is_derivative":false,"issuer_cik":"0001208570","issuer_name":"G1 Therapeutics, Inc.","issuer_ticker":"GTHX","issuer_name_source":null,"issuer_url":"/issuer/0001208570","owner_cik":null,"owner_name":"Reed Douglas MD; LEE KENNETH B JR; Thorp Clay; Crumpler John; INGRAM ROBERT ALEXANDER; Hatteras Venture Partners IV SBIC, LP; Hatteras Venture Advisors IV SBIC, LLC","owner_display_name":"Reed Douglas MD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":31100.0,"shares_display":"31,100","price_per_share":51.17078287781351,"price_display":"51.17","price_state":"stated","total_value":1591411.3475,"total_display":"1,591,411.35","total_whole":"1,591,411","shares_owned_after":4046206.0,"shares_owned_after_display":"4,046,206","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-21","filed_date":"2018-05-23","scope":"insider","n_lines":4},{"id":6473271,"accession":"0001209191-18-031802","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-031802","line_url":"/filing/0001209191-18-031802#line-2","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":61139.0,"shares_display":"61,139","price_per_share":13.16,"price_display":"13.16","price_state":"stated","total_value":804589.24,"total_display":"804,589.24","total_whole":"804,589","shares_owned_after":3466394.0,"shares_owned_after_display":"3,466,394","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-18","filed_date":"2018-05-21","scope":"insider"},{"id":6473268,"accession":"0001209191-18-031802","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-031802","line_url":"/filing/0001209191-18-031802#line-1","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":13.03,"price_display":"13.03","price_state":"stated","total_value":1303000.0,"total_display":"1,303,000.00","total_whole":"1,303,000","shares_owned_after":3527533.0,"shares_owned_after_display":"3,527,533","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-17","filed_date":"2018-05-21","scope":"insider"},{"id":6494581,"accession":"0001209191-18-021497","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-18-021497","line_url":"/filing/0001209191-18-021497#line-3","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5231.0,"shares_display":"5,231","price_per_share":12.02,"price_display":"12.02","price_state":"stated","total_value":62876.62,"total_display":"62,876.62","total_whole":"62,877","shares_owned_after":3627533.0,"shares_owned_after_display":"3,627,533","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-03-23","filed_date":"2018-03-23","scope":"insider"},{"id":6494579,"accession":"0001209191-18-021497","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-021497","line_url":"/filing/0001209191-18-021497#line-2","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":33630.0,"shares_display":"33,630","price_per_share":12.07,"price_display":"12.07","price_state":"stated","total_value":405914.1,"total_display":"405,914.10","total_whole":"405,914","shares_owned_after":3632764.0,"shares_owned_after_display":"3,632,764","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-03-22","filed_date":"2018-03-23","scope":"insider"},{"id":6494577,"accession":"0001209191-18-021497","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-021497","line_url":"/filing/0001209191-18-021497#line-1","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":12.27,"price_display":"12.27","price_state":"stated","total_value":1227000.0,"total_display":"1,227,000.00","total_whole":"1,227,000","shares_owned_after":3666394.0,"shares_owned_after_display":"3,666,394","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-03-21","filed_date":"2018-03-23","scope":"insider"},{"id":4231351,"accession":"0001209191-17-064491","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-17-064491","line_url":"/filing/0001209191-17-064491#line-3","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":6.13,"price_display":"6.13","price_state":"stated","total_value":30650.0,"total_display":"30,650.00","total_whole":"30,650","shares_owned_after":3766394.0,"shares_owned_after_display":"3,766,394","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-12-07","filed_date":"2017-12-07","scope":"insider"},{"id":4231345,"accession":"0001209191-17-064491","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-17-064491","line_url":"/filing/0001209191-17-064491#line-2","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":6.09,"price_display":"6.09","price_state":"stated","total_value":91350.0,"total_display":"91,350.00","total_whole":"91,350","shares_owned_after":3771394.0,"shares_owned_after_display":"3,771,394","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-12-06","filed_date":"2017-12-07","scope":"insider"},{"id":4231338,"accession":"0001209191-17-064491","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-064491","line_url":"/filing/0001209191-17-064491#line-1","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":6.37,"price_display":"6.37","price_state":"stated","total_value":95550.0,"total_display":"95,550.00","total_whole":"95,550","shares_owned_after":3786394.0,"shares_owned_after_display":"3,786,394","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-12-05","filed_date":"2017-12-07","scope":"insider"},{"id":4423627,"accession":"0001209191-17-061256","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-17-061256","line_url":"/filing/0001209191-17-061256#line-3","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":6.99,"price_display":"6.99","price_state":"stated","total_value":34950.0,"total_display":"34,950.00","total_whole":"34,950","shares_owned_after":3801394.0,"shares_owned_after_display":"3,801,394","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-11-16","filed_date":"2017-11-16","scope":"insider"},{"id":4423622,"accession":"0001209191-17-061256","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-17-061256","line_url":"/filing/0001209191-17-061256#line-2","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":6.99,"price_display":"6.99","price_state":"stated","total_value":104850.0,"total_display":"104,850.00","total_whole":"104,850","shares_owned_after":3806394.0,"shares_owned_after_display":"3,806,394","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-11-15","filed_date":"2017-11-16","scope":"insider"},{"id":4423619,"accession":"0001209191-17-061256","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-061256","line_url":"/filing/0001209191-17-061256#line-1","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":7.02,"price_display":"7.02","price_state":"stated","total_value":105300.0,"total_display":"105,300.00","total_whole":"105,300","shares_owned_after":3821394.0,"shares_owned_after_display":"3,821,394","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-11-14","filed_date":"2017-11-16","scope":"insider"},{"id":5176856,"accession":"0001209191-17-056207","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-17-056207","line_url":"/filing/0001209191-17-056207#line-3","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6000.0,"shares_display":"6,000","price_per_share":8.34,"price_display":"8.34","price_state":"stated","total_value":50040.0,"total_display":"50,040.00","total_whole":"50,040","shares_owned_after":3836394.0,"shares_owned_after_display":"3,836,394","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-10-05","filed_date":"2017-10-05","scope":"insider"},{"id":5176852,"accession":"0001209191-17-056207","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-17-056207","line_url":"/filing/0001209191-17-056207#line-2","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14000.0,"shares_display":"14,000","price_per_share":8.59,"price_display":"8.59","price_state":"stated","total_value":120260.0,"total_display":"120,260.00","total_whole":"120,260","shares_owned_after":3842394.0,"shares_owned_after_display":"3,842,394","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-10-04","filed_date":"2017-10-05","scope":"insider"},{"id":5176847,"accession":"0001209191-17-056207","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-056207","line_url":"/filing/0001209191-17-056207#line-1","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":8.64,"price_display":"8.64","price_state":"stated","total_value":129600.0,"total_display":"129,600.00","total_whole":"129,600","shares_owned_after":3856394.0,"shares_owned_after_display":"3,856,394","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-10-03","filed_date":"2017-10-05","scope":"insider"},{"id":4907082,"accession":"0001209191-17-053020","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-17-053020","line_url":"/filing/0001209191-17-053020#line-3","is_derivative":false,"issuer_cik":"0001539029","issuer_name":"Clearside Biomedical, Inc.","issuer_ticker":"CLSD","issuer_name_source":null,"issuer_url":"/issuer/0001539029","owner_cik":"0001592380","owner_name":"Thorp Clay","owner_display_name":"Thorp Clay","owner_url":"/insider/0001592380","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":7.54,"price_display":"7.54","price_state":"stated","total_value":75400.0,"total_display":"75,400.00","total_whole":"75,400","shares_owned_after":3871394.0,"shares_owned_after_display":"3,871,394","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-09-15","filed_date":"2017-09-15","scope":"insider"}],"collapsed":true,"next_cursor":"2017-09-15|4907082","ledger_fault":false,"count":{"value":66,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":16,"open_market":true},{"code":"S","label":"Open-market sale","n":50,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":66},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001539029","name":"Clearside Biomedical, Inc.","url":"/issuer/0001539029","role":"Director, Ten percent owner, Other","n_filings":25,"first_seen":"2016-06-07","last_seen":"2025-02-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001827087","name":"Vigil Neuroscience, Inc.","url":"/issuer/0001827087","role":"Director","n_filings":3,"first_seen":"2022-01-11","last_seen":"2022-05-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001169245","name":"PhaseBio Pharmaceuticals Inc","url":"/issuer/0001169245","role":"Director, Ten percent owner","n_filings":6,"first_seen":"2018-10-24","last_seen":"2021-08-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001560241","name":"G1 Therapeutics, Inc.","url":"/issuer/0001560241","role":"Ten percent owner","n_filings":3,"first_seen":"2017-05-24","last_seen":"2018-06-01"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001592380","retrieved_at":"2026-08-27T01:19:32+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}